HomeCompareRGLS vs FCPT

RGLS vs FCPT: Dividend Comparison 2026

RGLS yields 24.51% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RGLS wins by $46.9K in total portfolio value
10 years
RGLS
RGLS
● Live price
24.51%
Share price
$8.16
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$95.9K
Annual income
$10,627.09
Full RGLS calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — RGLS vs FCPT

📍 RGLS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRGLSFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RGLS + FCPT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RGLS pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RGLS
Annual income on $10K today (after 15% tax)
$2,083.33/yr
After 10yr DRIP, annual income (after tax)
$9,033.03/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, RGLS beats the other by $4,124.04/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RGLS + FCPT for your $10,000?

RGLS: 50%FCPT: 50%
100% FCPT50/50100% RGLS
Portfolio after 10yr
$72.5K
Annual income
$8,201.19/yr
Blended yield
11.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on RGLS right now

RGLS
Analyst Ratings
9
Buy
9
Hold
Consensus: Buy
Price Target
$7.00
-14.2% upside vs current
Range: $7.00 — $7.00
Altman Z
46.8
Piotroski
1/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RGLS buys
0
FCPT buys
0
No recent congressional trades found for RGLS or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRGLSFCPT
Forward yield24.51%6.05%
Annual dividend / share$2.00$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$95.9K$49.1K
Annual income after 10y$10,627.09$5,775.28
Total dividends collected$60.2K$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$7.00$27.00

Year-by-year: RGLS vs FCPT ($10,000, DRIP)

YearRGLS PortfolioRGLS Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$13,151$2,450.98$11,401$700.92+$1.8KRGLS
2$17,084$3,012.41$13,064$864.84+$4.0KRGLS
3$21,937$3,657.30$15,051$1,072.48+$6.9KRGLS
4$27,862$4,389.03$17,442$1,337.22+$10.4KRGLS
5$35,022$5,209.71$20,340$1,677.08+$14.7KRGLS
6$43,593$6,120.11$23,880$2,116.57+$19.7KRGLS
7$53,765$7,119.64$28,241$2,689.36+$25.5KRGLS
8$65,734$8,206.35$33,660$3,442.07+$32.1KRGLS
9$79,713$9,376.98$40,456$4,439.95+$39.3KRGLS
10$95,920$10,627.09$49,063$5,775.28+$46.9KRGLS

RGLS vs FCPT: Complete Analysis 2026

RGLSStock

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Full RGLS Calculator →

FCPTREIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this RGLS vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RGLS vs SCHDRGLS vs JEPIRGLS vs ORGLS vs KORGLS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.